Sunshine Biopharma (SBFM) director Keller to leave board
Rhea-AI Filing Summary
Sunshine Biopharma Inc. (SBFM) reported that on August 25, 2026, director Dr. Andrew Keller informed the company he will not seek or accept reelection to the Board of Directors after his current term ends. His term will expire at the company’s next annual shareholder meeting, at which point he will leave the board.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Terms
Emerging growth company, Section 12(b) of the Act, Common Stock Purchase Warrants
3 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 12(b) of the Act regulatory
"Securities registered pursuant to Section 12(b) of the Act"
Common Stock Purchase Warrants financial
"Common Stock Purchase Warrants | SBFMW | The Nasdaq Stock Market LLC"
Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.
FAQ
What director change did Sunshine Biopharma Inc. (SBFM) disclose?
Sunshine Biopharma Inc. disclosed that director Dr. Andrew Keller notified the company on August 25, 2026 that he will not be seeking or accepting reelection to the Board of Directors when his current term expires at the next annual shareholder meeting.
When will Dr. Andrew Keller leave the SBFM Board of Directors?
Dr. Andrew Keller’s current term on Sunshine Biopharma Inc.’s Board of Directors will expire at the company’s next annual shareholder meeting. At that time he will not stand for reelection and will leave the board.
Did Sunshine Biopharma Inc. (SBFM) report an immediate director resignation?
No. Sunshine Biopharma Inc. reported that Dr. Andrew Keller will serve out his current term and will not seek or accept reelection at the next annual shareholder meeting, rather than resigning immediately.
Which officer signed the Sunshine Biopharma Inc. (SBFM) 8-K about the director change?
The report was signed for Sunshine Biopharma Inc. by Dr. Steve N. Slilaty, Chief Executive Officer, dated August 28, 2026, in accordance with the requirements of the Securities Exchange Act of 1934.
What is the main purpose of this Sunshine Biopharma Inc. (SBFM) 8-K?
The main purpose is to disclose under Item 5.02 that director Dr. Andrew Keller has notified Sunshine Biopharma Inc. that he will not seek or accept reelection to the Board of Directors when his current term ends at the next annual shareholder meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
